Floatz logo

immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens KLK2 (kallikrein-2, kallikrein related peptidase 2, kallikrein 2 prostatic) and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], Homo sapiens and humanized monoclonal antibody, bispecific, bivalent

Adenocarcinoma

Janssen Research & Development, LLCmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

26 Active assets in the Adenocarcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 4BBB
Carboplatin
Blueprint Medicines Corporation
Phase 4BBB
Irinotecan
University of Chicago
Phase 2BBB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens KLK2 (kallikrein-2, kallikrein related peptidase 2, kallikrein 2 prostatic) and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], Homo sapiens and humanized monoclonal antibody, bispecific, bivalent is also rated in:

castration-resistant prostate carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
43 / 100
View asset →
prostate neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →